Pharsight

Drugs facing NCE-1 in 2023

1. List of Accrufer drug patents

ACCRUFER's oppositions filed in EPO
new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9802973 SHIELD TX Crystalline forms of ferric maltol
Oct, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248148 SHIELD TX Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections
Mar, 2031

(7 years from now)

US10179120 SHIELD TX Dosage regimen of ferric trimaltol
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 25, 2024

Drugs and Companies using FERRIC MALTOL ingredient

NCE-1 date: 2023-07-26

Market Authorisation Date: 25 July, 2019

Treatment: Method of treating iron deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage

ACCRUFER family patents

6

Japan

5

United States

5

United Kingdom

4

China

4

European Union

3

Canada

3

Australia

2

Spain

2

Korea, Republic of

2

Singapore

1

Brazil

EA

1

EA

1

Saudi Arabia

1

Chile

1

Israel

1

Slovenia

1

Mexico

1

South Africa

1

Poland

IB

1

IB

new

2. List of Aklief drug patents

AKLIEF's oppositions filed in EPO
new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7807708 GALDERMA LABS LP Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof
Oct, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8227507 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(2 years from now)

US8470871 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(2 years from now)

US9084778 GALDERMA LABS LP Topical compositions containing a retinoid of the oil-in-water emulsion type
May, 2033

(9 years from now)

US9498465 GALDERMA LABS LP Topical compositions in the form of a gel containing a particular solubilized retinoid
May, 2033

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 4, 2024

Drugs and Companies using TRIFAROTENE ingredient

NCE-1 date: 2023-10-05

Market Authorisation Date: 04 October, 2019

Treatment: Topical treatment of acne vulgaris; Method of activating rargamma receptor; Treatment of acne vulgaris

Dosage: CREAM;TOPICAL

More Information on Dosage

AKLIEF family patents

8

United States

6

European Union

3

France

3

China

3

Canada

3

Brazil

3

Korea, Republic of

3

Japan

3

Australia

3

Mexico

3

Russia

2

Spain

2

South Africa

1

Cyprus

1

New Zealand

1

Portugal

1

Netherlands

1

Chile

1

Hong Kong

1

Lithuania

1

Israel

1

Austria

1

Hungary

1

Slovenia

1

Argentina

1

Poland

1

Singapore

1

Denmark

new

3. List of Balversa drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8895601 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
May, 2031

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9464071 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
Apr, 2031

(7 years from now)

US9902714 JANSSEN BIOTECH Quinoxaline derivatives useful as FGFR kinase modulators
Mar, 2035

(11 years from now)

US10898482 JANSSEN BIOTECH Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
Feb, 2036

(12 years from now)

US11077106 JANSSEN BIOTECH Cancer treatment
Feb, 2038

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 2023-04-13

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemot...

Dosage: TABLET;ORAL

More Information on Dosage

BALVERSA family patents

18

United States

14

European Union

7

Singapore

6

China

6

Israel

6

Australia

5

RS

5

Portugal

5

Spain

5

Croatia

5

Jordan

EA

5

EA

5

Korea, Republic of

5

Japan

5

Lithuania

5

Hungary

5

Slovenia

5

Denmark

5

Mexico

5

Poland

5

Taiwan

4

Canada

4

Ukraine

4

Costa Rica

4

Morocco

3

Brazil

3

Chile

3

Argentina

3

Philippines

3

Nicaragua

2

Cyprus

2

New Zealand

2

United Kingdom

2

South Africa

1

Ecuador

1

Turkey

1

India

1

Malaysia

1

Hong Kong

1

ME

1

Colombia

AP

1

AP

new

4. List of Brukinsa drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9447106 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
Apr, 2034

(10 years from now)

US10570139 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(10 years from now)

US11142528 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(10 years from now)

US10927117 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11591340 BEIGENE NA
Aug, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
Orphan Drug Exclusivity (ODE) Sep 14, 2028
New Indication (I) Sep 14, 2024

Drugs and Companies using ZANUBRUTINIB ingredient

NCE-1 date: 2023-11-15

Market Authorisation Date: 14 November, 2019

Treatment: For the treatment of patients with waldenstrom's macroglobulinemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with...

Dosage: CAPSULE;ORAL

More Information on Dosage

BRUKINSA family patents

12

United States

5

China

3

Japan

3

Australia

2

Canada

2

Brazil

EA

2

EA

2

Korea, Republic of

2

Lithuania

2

Israel

2

Hungary

2

Mexico

2

South Africa

2

Singapore

2

European Union

1

New Zealand

1

Cyprus

1

RS

1

Portugal

1

Netherlands

1

Spain

1

Croatia

1

Hong Kong

1

Slovenia

1

Taiwan

1

Poland

IB

1

IB

1

Denmark

new

5. List of Caplyta drug patents

CAPLYTA's oppositions filed in EPO
Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE48825 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Feb, 2029

(5 years from now)

US9586960 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Mar, 2029

(5 years from now)

US8648077 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Dec, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10464938 INTRA-CELLULAR Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof
Mar, 2028

(4 years from now)

US9199995 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Mar, 2029

(5 years from now)

US9616061 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(5 years from now)

US10117867 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(5 years from now)

US8598119 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
Dec, 2029

(6 years from now)

USRE48839 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
Dec, 2029

(6 years from now)

US10960009 INTRA-CELLULAR Methods of treating schizophrenia and depression
Dec, 2034

(11 years from now)

US11026951 INTRA-CELLULAR Methods of treating bipolar disorder
Dec, 2034

(11 years from now)

US9956227 INTRA-CELLULAR Method for the treatment of residual symptoms of schizophrenia
Dec, 2034

(11 years from now)

US11052084 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(16 years from now)

US10695345 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 20, 2024
New Indication (I) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 2023-12-21

Market Authorisation Date: 20 December, 2019

Treatment: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression; Treatment of schizophrenia; Treatment of bipolar i disorder, bipolar ii disorder, or bipolar de...

Dosage: CAPSULE;ORAL

More Information on Dosage

CAPLYTA family patents

50

United States

19

Korea, Republic of

14

Japan

13

Australia

9

China

8

European Union

7

Canada

6

Mexico

5

Israel

3

Spain

3

Denmark

2

Portugal

2

Hong Kong

2

Poland

1

Brazil

1

India

1

Croatia

1

Hungary

1

Slovenia

1

Russia

new

6. List of Dalvance drug patents

DALVANCE's oppositions filed in EPO
new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7115564 ALLERGAN Stable pharmaceutical compositions of dalbavancin and methods of administration
Nov, 2023

(5 months from now)

US8143212 ALLERGAN Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(5 months from now)

US7119061 ALLERGAN Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(5 months from now)

US6900175 ALLERGAN Methods of administering dalbavancin for treatment of bacterial infections
May, 2028

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 23, 2019
New Patient Population (NPP) Jul 22, 2024
Generating Antibiotic Incentives Now (GAIN) May 23, 2024

Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient

NCE-1 date: 2023-05-24

Market Authorisation Date: 23 May, 2014

Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

DALVANCE family patents

28

United States

5

Japan

5

Australia

4

Korea, Republic of

3

China

3

Hong Kong

3

Israel

3

South Africa

3

Russia

2

New Zealand

2

Canada

2

Norway

2

Mexico

2

European Union

1

Portugal

1

Brazil

1

Spain

1

Hungary

1

Singapore

1

Denmark

new

7. List of Exem Foam Kit drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034300 GISKIT Composition and method for medical imaging of body cavities
Oct, 2030

(7 years from now)

US9259494 GISKIT Composition and method for medical imaging of body cavities
May, 2035

(11 years from now)

US9849199 GISKIT Composition and method for medical imaging of body cavities
Feb, 2036

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 7, 2024

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: 2023-11-08

Market Authorisation Date: 07 November, 2019

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

More Information on Dosage

EXEM FOAM KIT family patents

4

United States

2

Netherlands

1

Spain

1

Poland

1

Denmark

1

European Union

new

8. List of Givlaari drug patents

GIVLAARI's oppositions filed in EPO
GIVLAARI Litigations
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of a target gene
Jan, 2022

(1 year, 4 months ago)

US9708610 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(6 months from now)

US9708615 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(8 months from now)

US10273477 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(8 months from now)

US11530408 ALNYLAM PHARMS INC Therapeutic compositions
May, 2024

(11 months from now)

US9150605 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Aug, 2025

(2 years from now)

US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(6 years from now)

US10125364 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(9 years from now)

US9133461 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
May, 2033

(9 years from now)

US10119143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(11 years from now)

US11028392 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9631193 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 20, 2024
Orphan Drug Exclusivity (ODE) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 2023-11-21

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GIVLAARI family patents

273

United States

70

European Union

54

Australia

51

Japan

33

Canada

23

Germany

9

China

9

Spain

8

Denmark

7

Austria

6

Portugal

6

Korea, Republic of

6

Israel

6

South Africa

5

Hong Kong

4

Cyprus

4

Chile

3

Brazil

3

Lithuania

3

Hungary

3

Argentina

3

Mexico

2

New Zealand

2

Dominican Republic

2

Croatia

2

Peru

2

Slovenia

2

Poland

2

Taiwan

2

Russia

2

Singapore

1

RS

1

Netherlands

EA

1

EA

1

Ukraine

1

Guatemala

1

ME

1

Costa Rica

1

Tunisia

1

Morocco

1

Philippines

1

Colombia

new

9. List of Ibsrela drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8969377 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Dec, 2029

(6 years from now)

US8541448 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Aug, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408840 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder
Dec, 2029

(6 years from now)

US9006281 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
May, 2030

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 12, 2024

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

NCE-1 date: 2023-09-13

Market Authorisation Date: 12 September, 2019

Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor

Dosage: TABLET;ORAL

More Information on Dosage

IBSRELA family patents

13

United States

5

Korea, Republic of

3

Israel

3

European Union

2

China

2

Japan

2

Mexico

1

Cyprus

1

Portugal

1

Canada

1

Brazil

1

Norway

1

Spain

1

Croatia

1

Hong Kong

1

Lithuania

1

Hungary

1

Slovenia

1

Australia

1

Poland

1

Denmark

new

10. List of Inrebic drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7528143 IMPACT Bi-aryl meta-pyrimidine inhibitors of kinases
Dec, 2026

(3 years from now)

US7825246 IMPACT Bi-aryl meta-pyrimidine inhibitors of kinases
Dec, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8138199 IMPACT Use of bi-aryl meta-pyrimidine inhibitors of kinases
Jun, 2028

(5 years from now)

US10391094 IMPACT Compositions and methods for treating myelofibrosis
Jun, 2032

(8 years from now)

US11400092 IMPACT Methods of treating myeloproliferative disorders
Sep, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 16, 2026
New Chemical Entity Exclusivity (NCE) Aug 16, 2024

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

NCE-1 date: 2023-08-17

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis; Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring...

Dosage: CAPSULE;ORAL

More Information on Dosage

INREBIC family patents

21

United States

6

Korea, Republic of

5

China

5

Brazil

4

Japan

4

Ukraine

4

Australia

4

Russia

3

New Zealand

3

Canada

3

Lithuania

3

Israel

3

European Union

2

Spain

2

Malaysia

2

Chile

2

Hungary

2

Denmark

2

Mexico

2

Taiwan

2

South Africa

2

Singapore

2

Morocco

1

Cyprus

1

Ecuador

1

Portugal

1

Norway

1

Netherlands

1

Dominican Republic

1

Croatia

EA

1

EA

1

Hong Kong

1

Peru

1

Tunisia

1

Nicaragua

1

Poland

1

Colombia

new

11. List of Kimyrsa drug patents

KIMYRSA's oppositions filed in EPO
new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin
Aug, 2029

(6 years from now)

US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(6 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 12, 2024
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 2023-08-07

Market Authorisation Date: 12 March, 2021

Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

KIMYRSA family patents

14

United States

4

China

4

European Union

3

Canada

3

Australia

3

Japan

2

Mexico

2

New Zealand

2

Hungary

EA

2

EA

2

Brazil

1

Netherlands

1

Spain

1

Norway

1

Poland

1

Hong Kong

1

Denmark

new

12. List of Mayzent drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7939519 NOVARTIS Immunosuppresant compounds and compositions
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441 NOVARTIS Dosage regimen of an S1P receptor agonist
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 26, 2024
M (M) Mar 1, 2025

Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient

NCE-1 date: 2023-03-27

Market Authorisation Date: 26 March, 2019

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose

Dosage: TABLET;ORAL

More Information on Dosage

MAYZENT family patents

17

United States

11

Australia

11

European Union

8

China

7

Canada

7

Japan

6

Mexico

5

Brazil

5

Spain

4

Hong Kong

3

Cyprus

3

Portugal

3

Israel

3

Hungary

3

Slovenia

3

Argentina

3

Taiwan

3

Poland

3

Russia

3

Denmark

2

New Zealand

2

Norway

2

Croatia

2

Chile

2

Korea, Republic of

2

Lithuania

2

Peru

2

Tunisia

2

Morocco

2

South Africa

1

Ecuador

1

Uruguay

1

Netherlands

1

Malaysia

1

Jordan

1

Austria

1

Iceland

1

Singapore

1

Luxembourg

new

13. List of Nourianz drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7541363 KYOWA KIRIN Microcrystal
Nov, 2024

(1 year, 5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7727994 KYOWA KIRIN Methods of treating patients suffering from movement disorders
Jan, 2023

(4 months ago)

US7727993 KYOWA KIRIN Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy
Jan, 2023

(4 months ago)

US8318201 KYOWA KIRIN Method of stabilizing diarylvinylene compound
Sep, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 27, 2024

Drugs and Companies using ISTRADEFYLLINE ingredient

NCE-1 date: 2023-08-28

Market Authorisation Date: 27 August, 2019

Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives ...

Dosage: TABLET;ORAL

More Information on Dosage

NOURIANZ family patents

11

United States

10

Japan

8

Korea, Republic of

6

European Union

5

China

4

Australia

4

Spain

4

Canada

2

Hungary

2

Portugal

1

Mexico

1

Austria

1

Taiwan

1

Colombia

EA

1

EA

1

Argentina

1

Turkey

1

Brazil

new

14. List of Nubeqa drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11046713 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US9657003 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US10711013 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US8975254 BAYER HEALTHCARE Androgen receptor modulating compounds
Mar, 2033

(9 years from now)

US10010530 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(12 years from now)

US10383853 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(12 years from now)

US11168058 BAYER HEALTHCARE Manufacture of a crystalline pharmaceutical product
Feb, 2038

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835515 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 30, 2024
New Indication (I) Aug 5, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: 2023-07-31

Market Authorisation Date: 30 July, 2019

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

NUBEQA family patents

16

United States

14

European Union

5

Portugal

5

Spain

5

Japan

5

Hungary

5

Slovenia

5

Finland

5

Poland

5

Denmark

4

RS

4

China

4

Brazil

4

Croatia

4

Korea, Republic of

4

Lithuania

3

Canada

3

Ukraine

3

Israel

3

Australia

2

Cyprus

2

Chile

EA

2

EA

2

Hong Kong

2

Mexico

2

South Africa

1

New Zealand

1

San Marino

1

Georgia

1

Norway

1

Netherlands

1

Malaysia

1

Peru

1

Argentina

1

Russia

1

Colombia

1

Luxembourg

new

15. List of Orbactiv drug patents

ORBACTIV's oppositions filed in EPO
new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin
Aug, 2029

(6 years from now)

US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(6 years from now)

US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 2023-08-07

Market Authorisation Date: 06 August, 2014

Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ORBACTIV family patents

14

United States

4

China

4

European Union

3

Canada

3

Australia

3

Japan

2

Mexico

2

New Zealand

2

Hungary

EA

2

EA

2

Brazil

1

Netherlands

1

Spain

1

Norway

1

Poland

1

Hong Kong

1

Denmark

new

16. List of Oxbryta drug patents

OXBRYTA's oppositions filed in EPO
new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10806733 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(9 years from now)

US10034879 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(9 years from now)

US9018210 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Nov, 2033

(10 years from now)

US9447071 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10017491 GLOBAL BLOOD THERAPS Compounds and uses thereof for the modulation of hemoglobin
Dec, 2032

(9 years from now)

US9248199 GLOBAL BLOOD THERAPS 1:1 adducts of sickle hemoglobin
Jan, 2034

(10 years from now)

US10722502 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(11 years from now)

US11452720 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(11 years from now)

US11020382 GLOBAL BLOOD THERAPS Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Dec, 2036

(13 years from now)

US10493035 GLOBAL BLOOD THERAPS Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Oct, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 25, 2026
New Chemical Entity Exclusivity (NCE) Nov 25, 2024

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: 2023-11-26

Market Authorisation Date: 25 November, 2019

Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 1; Treatment of sickle cell disease by administering voxelotor, as recited in claim 2; Treating sickle cell disease by ...

Dosage: TABLET;ORAL

More Information on Dosage

OXBRYTA family patents

67

United States

18

Japan

15

Australia

15

Singapore

13

Taiwan

12

China

12

European Union

10

Israel

EA

9

EA

8

Brazil

8

Korea, Republic of

8

Peru

8

Argentina

8

Mexico

7

Canada

7

Spain

4

Uruguay

4

Saudi Arabia

4

Lithuania

4

Hungary

3

RS

3

Portugal

3

Croatia

3

Chile

3

Slovenia

3

Poland

3

South Africa

3

Denmark

2

Malaysia

2

Morocco

1

New Zealand

1

Cyprus

1

Netherlands

1

Norway

1

Hong Kong

1

Guatemala

1

Nicaragua

1

Colombia

new

17. List of Piqray drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476268 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2029

(6 years from now)

US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 24, 2024

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: 2023-05-25

Market Authorisation Date: 24 May, 2019

Treatment: In combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

PIQRAY family patents

5

United States

3

European Union

2

Cyprus

2

Hungary

2

Argentina

1

New Zealand

1

San Marino

1

Ecuador

1

RS

1

Uruguay

1

Georgia

1

Panama

1

China

1

Portugal

1

Brazil

1

Canada

1

Norway

1

Spain

1

Netherlands

1

Dominican Republic

1

Malaysia

1

Croatia

1

Jordan

1

Hong Kong

1

Chile

EA

1

EA

1

Korea, Republic of

1

Japan

1

Lithuania

1

Ukraine

1

Honduras

1

ME

1

Israel

1

Costa Rica

1

Peru

1

Slovenia

1

Tunisia

1

Morocco

1

Cuba

1

Australia

1

Mexico

1

Nicaragua

1

Poland

1

South Africa

1

Taiwan

1

Colombia

1

El Salvador

1

Denmark

new

18. List of Rinvoq drug patents

RINVOQ's oppositions filed in EPO
new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47221 ABBVIE INC Tricyclic compounds
Dec, 2030

(7 years from now)

US8962629 ABBVIE INC Tricyclic compounds
Jan, 2031

(7 years from now)

US11186584 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10981923 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US9951080 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10344036 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10981924 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US9963459 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof
Oct, 2036

(13 years from now)

US10550126 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10995095 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10597400 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10519164 ABBVIE INC Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11198697 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10730883 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11365198 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10202393 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11512092 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 14, 2024
New Chemical Entity Exclusivity (NCE) Aug 16, 2024

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: 2023-08-17

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products,...

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

RINVOQ family patents

60

United States

10

Singapore

9

Japan

8

China

8

Australia

7

Canada

7

European Union

6

Korea, Republic of

6

Israel

6

Taiwan

5

Russia

4

Brazil

4

Dominican Republic

3

New Zealand

3

Hong Kong

3

Ukraine

3

Costa Rica

3

Hungary

3

Peru

3

Argentina

3

Mexico

2

Cyprus

2

Ecuador

2

RS

2

Uruguay

2

Portugal

2

Norway

2

Spain

2

Malaysia

2

Croatia

2

ME

2

Chile

2

Lithuania

2

Slovenia

2

Poland

2

South Africa

2

Colombia

2

Denmark

1

Netherlands

1

Philippines

1

Luxembourg

new

19. List of Rinvoq drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11524964 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11535624 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11535625 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11535626 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11607411 ABBVIE Methods of treating Crohn's disease and ulcerative colitis
Mar, 2038

(14 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 14, 2024
New Chemical Entity Exclusivity (NCE) Aug 16, 2024

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: 2023-08-17

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with moderately to severely active rheumatoid...

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

20. List of Rozlytrek drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9029356 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US8299057 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Mar, 2029

(5 years from now)

US9085565 GENENTECH INC Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(9 years from now)

US10738037 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9085558 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US9255087 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US9616059 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US8673893 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US9649306 GENENTECH INC Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(9 years from now)

US10231965 GENENTECH INC Molecules for administration to ROS1 mutant cancer cells
Feb, 2035

(11 years from now)

US10561651 GENENTECH INC Methods for treating neuroblastoma
Feb, 2035

(11 years from now)

US11091469 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(13 years from now)

US10398693 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(15 years from now)

US11253515 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 15, 2026
New Chemical Entity Exclusivity (NCE) Aug 15, 2024

Drugs and Companies using ENTRECTINIB ingredient

NCE-1 date: 2023-08-16

Market Authorisation Date: 15 August, 2019

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; Treatment of neuroblastomas that have a neurotrop...

Dosage: CAPSULE;ORAL

More Information on Dosage

ROZLYTREK family patents

32

United States

16

European Union

7

China

7

Korea, Republic of

6

Japan

6

Israel

6

Australia

5

Canada

5

Spain

5

Poland

4

New Zealand

4

Brazil

4

Hong Kong

4

Taiwan

3

Mexico

2

Netherlands

2

Chile

EA

2

EA

2

Ukraine

2

Hungary

2

Argentina

2

Singapore

1

Portugal

1

Norway

1

Slovenia

1

Philippines

1

South Africa

1

Russia

1

Denmark

new

21. List of Scenesse drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076555 CLIVUNEL INC Methods of inducing melanogenesis in a subject
Feb, 2025

(1 year, 8 months from now)

US8334265 CLIVUNEL INC Method of treatment of photodermatoses
Mar, 2029

(5 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 8, 2026
New Chemical Entity Exclusivity (NCE) Oct 8, 2024

Drugs and Companies using AFAMELANOTIDE ingredient

NCE-1 date: 2023-10-09

Market Authorisation Date: 08 October, 2019

Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)

Dosage: IMPLANT;SUBCUTANEOUS

More Information on Dosage

SCENESSE family patents

6

Australia

6

United States

3

Spain

3

Slovenia

3

Denmark

3

European Union

2

New Zealand

2

Hungary

2

Poland

2

Portugal

2

Canada

1

Cyprus

1

Netherlands

1

South Africa

1

China

1

Luxembourg

1

Hong Kong

1

Japan

new

22. List of Sivextro drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420676 CUBIST PHARMS LLC Oxazolidinone derivatives
Feb, 2028

(4 years from now)

US7816379 CUBIST PHARMS LLC Oxazolidinone derivatives
Jun, 2028

(5 years from now)

US9624250 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(6 years from now)

US10442829 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(6 years from now)

US8426389 CUBIST PHARMS LLC Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10065947 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(6 years from now)

US9988406 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 20, 2019
New Patient Population (NPP) Jun 19, 2023
Generating Antibiotic Incentives Now (GAIN) Jun 20, 2024

Drugs and Companies using TEDIZOLID PHOSPHATE ingredient

NCE-1 date: 2023-06-21

Market Authorisation Date: 20 June, 2014

Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

SIVEXTRO family patents

18

United States

6

China

6

Korea, Republic of

5

New Zealand

4

Russia

3

Spain

3

Australia

3

Mexico

3

European Union

2

Canada

2

Brazil

2

Hong Kong

2

Japan

2

South Africa

2

Singapore

1

Cyprus

1

Ecuador

1

Portugal

1

Dominican Republic

1

Netherlands

1

Malaysia

1

Chile

1

Lithuania

1

Ukraine

1

Israel

1

Austria

1

Costa Rica

AP

1

AP

1

Hungary

1

Peru

1

Slovenia

1

Tunisia

1

Morocco

1

Philippines

1

Cuba

1

Poland

1

Colombia

1

Luxembourg

1

Denmark

new

23. List of Sunosi drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10351517 JAZZ Treatment of sleep-wake disorders
Jun, 2026

(3 years from now)

US9604917 JAZZ Treatment of sleep-wake disorders
Jun, 2026

(3 years from now)

US8877806 JAZZ Treatment of sleep-wake disorders
Jun, 2026

(3 years from now)

US8440715 JAZZ Treatment of sleep-wake disorders
Aug, 2027

(4 years from now)

US10512609 JAZZ Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(14 years from now)

US10195151 JAZZ Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(14 years from now)

US10912754 JAZZ Methods and compositions for treating excessive sleepiness
Jun, 2038

(14 years from now)

US10959976 JAZZ Methods and compositions for treating excessive sleepiness
Jun, 2038

(14 years from now)

US10940133 JAZZ Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); Treatment of excessive daytime sleepiness associated with obstru...

Dosage: TABLET;ORAL

More Information on Dosage

SUNOSI family patents

20

United States

3

China

3

Canada

3

Korea, Republic of

3

Japan

3

Australia

3

European Union

2

Brazil

2

Philippines

2

Mexico

2

Taiwan

2

Russia

2

Denmark

1

Netherlands

1

Spain

1

Chile

1

Israel

1

Poland

1

Singapore

new

24. List of Sunosi drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439597 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(14 years from now)

US11560354 AXSOME MALTA Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof
Mar, 2039

(15 years from now)

US11160779 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness by adminstering a composition comprising solriamfetol hydrochloride and 2-chloropropane, wherein the composition comprises less than about 5 ppm 2-chloropropa...

Dosage: TABLET;ORAL

More Information on Dosage

SUNOSI family patents

6

United States

1

Australia

1

Israel

1

Mexico

1

Philippines

1

Russia

1

China

1

Singapore

1

Chile

1

Korea, Republic of

1

Japan

1

Denmark

1

Canada

1

European Union

new

25. List of Trikafta (copackaged) drug patents

TRIKAFTA (COPACKAGED)'s oppositions filed in EPO
new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US10239867 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(3 years from now)

US7645789 VERTEX PHARMS INC Indole derivatives as CFTR modulators
May, 2027

(3 years from now)

US8623905 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(3 years from now)

US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(3 years from now)

US7776905 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2027

(3 years from now)

US11426407 VERTEX PHARMS INC NA
Oct, 2035

(12 years from now)

US10758534 VERTEX PHARMS INC NA
Oct, 2035

(12 years from now)

US10793547 VERTEX PHARMS INC Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Dec, 2037

(14 years from now)

US11453655 VERTEX PHARMS INC Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Dec, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2025

(2 years from now)

US8354427 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jul, 2026

(3 years from now)

US9670163 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US9931334 VERTEX PHARMS INC Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US8410274 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US9974781 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(3 years from now)

US10022352 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(3 years from now)

US8598181 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(3 years from now)

US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Aug, 2027

(4 years from now)

US8415387 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Nov, 2027

(4 years from now)

US10646481 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

US11564916 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

US11578062 VERTEX PHARMS INC Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
Mar, 2031

(7 years from now)

US10081621 VERTEX PHARMS INC Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
Mar, 2031

(7 years from now)

US9012496 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
Jul, 2033

(10 years from now)

US11179367 VERTEX PHARMS INC Pharmaceutical compositions for treating cystic fibrosis
Dec, 2037

(14 years from now)

US11517564 VERTEX PHARMS INC Methods of treatment for cystic fibrosis
Dec, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jun 8, 2024
New Chemical Entity Exclusivity (NCE) Oct 21, 2024
Orphan Drug Exclusivity (ODE) Dec 21, 2027

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

NCE-1 date: 2023-10-22

Market Authorisation Date: 21 October, 2019

Treatment: Treatment of a moderate to mild clinical phenotype of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; Treatm...

Dosage: TABLET;ORAL

More Information on Dosage

TRIKAFTA (COPACKAGED) family patents

118

United States

39

European Union

28

Japan

23

Australia

20

China

20

Israel

18

Spain

16

Canada

16

Hungary

15

New Zealand

14

Portugal

14

Slovenia

14

Mexico

14

Poland

14

Denmark

13

Lithuania

12

Russia

11

RS

11

Brazil

11

Croatia

9

Cyprus

8

Hong Kong

7

Korea, Republic of

6

ME

6

Morocco

5

Taiwan

5

South Africa

5

Singapore

EA

4

EA

4

Chile

4

Argentina

3

Colombia

2

Uruguay

2

Norway

2

Ukraine

1

Ecuador

1

India

1

Netherlands

1

Jordan

1

Saudi Arabia

1

Peru

1

Moldova, Republic of

1

Luxembourg

new

26. List of Turalio drug patents

new
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8722702 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(4 years from now)

US8404700 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(4 years from now)

US9169250 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(4 years from now)

US7893075